MANE
Veradermics, Incorporated NYSE$101.00
Mkt Cap $20.3B
52w Low $32.00
83.6% of range
52w High $114.50
50d MA $61.38
200d MA $58.29
P/E (TTM)
-721.4x
EV/EBITDA
-291.4x
P/B
372.0x
Debt/Equity
0.0x
ROE
57.8%
P/FCF
-320.9x
RSI (14)
—
ATR (14)
—
Beta
0.00
50d MA
$61.38
200d MA
$58.29
Avg Volume
446.4K
About
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the dev…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -1.81 | -1.06 | +41.5% | 60.85 | +1.0% | +3.8% | -3.4% | +5.5% | +4.9% | -6.8% | +75.1% | — |
| Feb 25, 2026 | AMC | -1.81 | -1.62 | +10.3% | 42.17 | +0.0% | +1.8% | +8.7% | +10.6% | +6.9% | +12.3% | +55.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $73.35 | $75.05 | +2.3% | -4.1% | -5.6% | -7.5% | +36.5% | +40.6% |
Recent Filings
8-K · 1.01
!! High
Veradermics, Incorporated -- 8-K 1.01: Material Agreement
I don't have enough information from this truncated summary to provide a meaningful analysis. The summary appears incomplete ("THE HOLDER HEREBY IRREVOCAB..."). Please provide the full summary for an accurate investor explanation.
May 1
8-K
Veradermics, Incorporated -- 8-K Filing
I cannot provide a meaningful investor analysis as the filing summary lacks substantive information about Veradermics' business developments, financial results, or material events.
Apr 27
8-K · 8.01
!! High
Veradermics, Incorporated -- 8-K 8.01: Material Event / Announcement
Veradermics announced positive Phase 2/3 data for VDPHL01 treating male pattern hair loss, potentially advancing the treatment toward regulatory approval and market commercialization.
Apr 27
8-K
Unknown — 8-K Filing
MANE's multiple late-stage pipeline catalysts in 2024—including two Phase 3 readouts and potential NDA submission—offer significant upside if successful, justifying investor patience with clinical execution risk.
Mar 30
8-K · 5.03
! Medium
Veradermics, Incorporated -- 8-K 5.03: Amendment to Articles / Bylaws
Veradermics, Incorporated changed its fiscal year end, which may affect the timing of financial reporting and earnings announcements for investors monitoring MANE stock.
Feb 5
Data updated apr 25, 2026 8:30pm
· Source: massive.com